In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > BUSINESS
BUSINESS
- Pfizer Japan to Launch 2 Generic APIs on Feb 8, Total 18 APIs
February 6, 2012
- OncoTherapy to Jointly Initiate PIII Study for OCV-C01 with Otsuka
February 6, 2012
- US, European Pharmaceutical Companies Supported by Steady Japan Business Growth
February 6, 2012
- Lipitor Generics Have Over 6% of Negative Impact: Astellas
February 6, 2012
- Pfizer Highly Rated for Pharmacist Support: Nextit Research Survey
February 6, 2012
- Mr Tsuchiya of Eisai Disapproves Virtual Permission of Off-label Use of Generics Not Approved for the Same Indications as Their Original Drugs
February 6, 2012
- Chugai Pharmaceutical Dec 2011 Sales Decline After Earthquake Despite Steady Sales Abroad
February 6, 2012
- Number of MRs Breaks 60,000; Could Become Major Topic in Light of Strained Healthcare Finances
February 6, 2012
- Eisai Says Impact from Generic Versions of Aricept Insignificant
February 3, 2012
- Eisai's Apr-Dec Sales Down 17% on 50% Drop in Aricept Sales
February 3, 2012
- Pfizer to Offer Financial, Technical Support for Early Stage Development to External Institution
February 3, 2012
- Apr-Dec Sales Up 4%, Profits Show 2-Digit Increase due to Growth in Vesicare: Astellas
February 3, 2012
- Chugai to Restructure Marketing Div. to Achieve Targets in “Sunrise 2012” Plan
February 3, 2012
- New Granule Formulation of Fosrenol Obtains Approval: Bayer Yakuhin
February 3, 2012
- Janssen Files Application for Additional Subcutaneous Administration of Velcade
February 2, 2012
- Chugai Pharmaceutical to Promote Executive VP Kosaka as President and COO
February 2, 2012
- Astellas, UCB Form Partnership for Rheumatoid Arthritis Treatment Awaiting Approval
February 2, 2012
- Kyowa Kirin Sees Nesp as Core of Its Asian Strategy: President Matsuda
February 2, 2012
- Maruho, Asahi Kasei Pharma File Application for Add’l Indication of Herpes Simplex for Famvir
February 2, 2012
- Nycomed Acquisition Contributes to 4.3% Growth in Sales for April-December 2011: Takeda
February 2, 2012
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…